Asperuloside Improves Obesity and Type 2 Diabetes through Modulation of Gut Microbiota and Metabolic Signaling
Anna Nakamura, Yoko Yokoyama, Kazuki Tanaka, Giorgia Benegiamo, Akiyoshi Hirayama, Qi Zhu, Naho Kitamura, Taichi Sugizaki, Kohkichi Morimoto, Hiroshi Itoh, Shinji Fukuda, Johan Auwerx, Kazuo Tsubota, Mitsuhiro Watanabe
Abstract
is used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.